Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ103 Desensitisation in Highly Sensitised Kidney Transplant Candidates
ChiCTR2300079267Phase 3Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ricefidase in kidney allograft rejection and kidney transplant desensitization, sponsored by Huazhong University of Science and Technology. Primary endpoint: Reduction of pre-existing DSA to transplant-acceptable negative levels within 24 hours post-KJ103. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ricefidase
03
Conditions
kidney allograft rejectionkidney transplant desensitization
Beyond the preview
Go deeper on ChiCTR2300079267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079267.